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ABSTRACT 
Background: Tuberculosis is an infectious disease caused by the bacillus M. 
tuberculosis. It is a disease that mainly infects the lungs, however, almost any other organ 
of the body can be infected. Central nervous system TB is a severe form of 
extrapulmonary TB representing 5 – 15 % of all cases of extrapulmonary TB and accounts 
for approximately 1 % of all TB cases. Microglia, the resident macrophages of the CNS, 
are located within the cerebral parenchyma by the BBB. These cells play a role as the first 
barrier against intra-cerebral infections such as TB. It is unknown whether the 
susceptibility characteristics of M. tuberculosis strains affects the rate at which the 
bacteria migrate through the alveolar epithelium to other sites of the body. 
Materials and methods: M059K glial cells were cultured in a 24-well tissue culture plate 
then infected with different strains of M. tuberculosis (susceptible F1, MDR F28, 
susceptible and XDR Beijing, and susceptible, MDR and XDR F15/LAM4/KZN) at an 
MOI of 10. A549 alveolar epithelial cells and M059k glial cells were co-cultured in a 24-
well transwell plate. A549 cells were cultured on the insert membranes and M059K glial 
cells in the wells below the inserts. The A549 cell monolayers were exposed to the 
different strains. The H37Rv laboratory strain was included as a reference strain. 
Results: Invasion capacity, transmigration rate, adhesion and invasion rate following 
transmigration were established. The susceptible F15/LAM4/KZN and F11 strains 
showed a high invasion capacity for glial cells while the susceptible Beijing strain showed 
the lowest invasion capacity. The XDR strains displayed a greater transmigration rate 
over time. The MDR strains demonstrated lower transmigration rates compared to the 
susceptible strains. Only the susceptible Beijing strain did not show any transmigration 
ability. Following transmigration, the XDR strains demonstrated significantly high 
adhesion and invasion rates. The susceptible Beijing strain still did not show any 
dissemination ability. 
Discussion: We found differences in invasion capacity and transmigration ability 
between the different strains of M. tuberculosis. The invasion capacity of M. tuberculosis 
into glial cells could differ from that of M. tuberculosis directly inoculated onto the glial 
cells. This could be a result of structural changes on the bacterial surface while migrating 
through the epithelium. 
xi 
 
Conclusion: We conclude that M. tuberculosis isolates are able to pass through the 
epithelial lining of the alveoli to other body sites by transepithelial migration, and the 
XDR isolates pass A549 cells very effectively.
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1. Introduction 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis (M. tuberculosis). It is a disease that mainly infects the lungs, termed 
pulmonary TB, but almost any other organ of the body can be infected (Sarkar et al., 
2016). Tuberculosis that occurs at any other organ of the body apart from the lungs is 
termed extrapulmonary TB (Click et al., 2012; Lee, 2015; Sarkar et al., 2016). In 2017, 
the World Health Organisation (WHO) reported 6.4 million incident cases of TB globally 
and extrapulmonary TB represented 14 % of those cases (World Health Organisation, 
2018). Extrapulmonary TB develops as a secondary infection during the lymphatic or 
hematogenous spread of primary lung infection to other organs of the body (Sharma et 
al., 2005; Golden & Vikram, 2005; Qin et al., 2015). The most common extrapulmonary 
sites affected include the central nervous system (CNS), bones and joints, lymph nodes, 
pleura, genitourinary tract, peritoneum and other abdominal organs (Golden & Vikram, 
2005; Lee, 2015). 
Central nervous system TB (CNS-TB) is a severe form of extrapulmonary TB 
representing 5 – 15 % of all cases of extrapulmonary TB (Qin et al., 2015) and accounts 
for approximately 1 % of all TB cases (Rock et al., 2004; Rock et al., 2005; Cherian & 
Thomas, 2011; Spanos et al., 2015). The infection manifests as tuberculous meningitis in 
most cases but can also manifest as intracranial tuberculoma or spinal arachnoiditis 
(Golden & Vikram, 2005; Tucker et al., 2016). Tuberculous meningitis most commonly 
affects children, people infected with the human immunodeficiency virus (HIV), and the 
elderly, causing high rates of morbidity and mortality in these population groups (Rock 
et al., 2004; Cherian & Thomas, 2011; Spanos et al., 2015; Tucker et al., 2016). Microglia 
are the local macrophages of the CNS (Cannas et al., 2011; Spanos et al., 2015). They 
are located within the cerebral parenchyma by the blood-brain barrier (BBB) functioning 
as the first barrier against intra-cerebral infections such as TB (Cannas et al., 2011; 
Spanos et al., 2015). Cells of the macrophage lineage are the host’s primary target cells 
for M. tuberculosis and studies have demonstrated that they are efficiently invaded by 
this bacillus (Cannas et al., 2011; Qin et al., 2015; Tucker et al., 2016). 
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Associations between M. tuberculosis strains and tropism for extrapulmonary sites have 
been reported in some studies (Caws et al., 2008; Be et al., 2011; Click et al., 2012; Sarkar 
et al., 2016). These studies have demonstrated that the site of extrapulmonary TB is not 
only host dependent but also dependent on bacterial characteristics. Understanding of the 
mechanisms used by M. tuberculosis to pass through epithelial barriers during infection 
was improved by studies using in vitro models of mucosal barriers (Birkness et al., 1999; 
Bermudez et al., 2002; Ryndak et al., 2016). These studies have demonstrated how M. 
tuberculosis exploits the intracellular environment of alveolar epithelial cells to enhance 
its infectivity and to traverse the alveolar barrier, gaining access into the bloodstream. 
This allows the bacilli to infect organs other than the lungs. Although these studies have 
established the association of M. tuberculosis strains and their tropism for extrapulmonary 
sites, the mechanisms by which these M. tuberculosis strains transmigrate from the lung 
to extrapulmonary sites remains understudied. 
This is the first study to investigate the transmigration, from the lung to the brain, of 
endemic and globally relevant M. tuberculosis genotypes that spread in multidrug-
resistant (MDR) and extensively drug-resistant (XDR) forms. The F15/LAM4/KZN 
(KZN) genotype is one of those genotypes. It was reported for the first time in KwaZulu-
Natal Province, South Africa, in the early 1990s (Pillay & Sturm, 2007) and was 
responsible for the largest outbreak of XDR tuberculosis (XDR-TB) that occurred in 
Tugela Ferry, KwaZulu-Natal in 2005 (Gandhi et al., 2006). Other relevant genotypes 
include Beijing, F28, and F11. The Beijing genotype is globally disseminated and most 
prevalent in Asia (Bifani et al., 2002; Glynn et al., 2002; Hanekom et al., 2011). It is one 
of the most successfully spreading strains and is also associated with drug-resistant TB 
globally (Glynn et al., 2002; Hanekom et al., 2011; Chihota et al., 2012). The F28 and 
F11 genotypes have been reported in drug-resistant TB cases in the Western Cape 
Province, South Africa (Streicher et al., 2004; Nicol et al., 2005; Chihota et al., 2012). 
Although these strains have been reported in clinical cases of extrapulmonary TB, there 
is a lack of correlation between the relative transmigration levels and variation among 
these isolates in the pathogenesis of CNS-TB. 
Extrapulmonary TB develops in a minority of cases, and it was previously not clear 
whether this was host or microbe dependent. However, studies suggest that both host and 
microbial factors play a role in the pathogenesis of extrapulmonary TB. A recent study in 
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our Department demonstrated that some strains of M. tuberculosis had a higher affinity 
for osteoblasts, a cell derived from mesenchymal stem cells present in bone, supporting 
previous findings that the site of extrapulmonary TB is also microbe dependent (Sarkar 
et al., 2016). We extended this study by comparing the transmigration of KZN, F28, F11 
and Beijing strains, using an in vitro model comprised of human type II alveolar epithelial 
cells and human glial cells. Following transmigration, the bacteria were exposed to glial 
cells to evaluate the difference in affinity for glial cells among the strains to better 
understand which strain is more likely to cause tuberculosis in the CNS. 
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1.2. Literature review 
1.2.1. Epidemiology of tuberculosis 
According to WHO, an estimated 10 million people in the world developed TB in 2017. 
Amongst these people, 58 % were men, 32 % were women, and 10 % were children 
(World Health Organisation, 2018). Approximately 1.3 million people living without 
HIV have died from TB in 2017. Among all TB-related deaths, an additional 0.3 million 
deaths occurred among HIV-positive people (World Health Organisation, 2018). South 
Africa features on the three lists used by WHO to categorise countries with a high burden 
of TB, TB and HIV co-infection, and multidrug-resistant TB (MDR-TB). Approximately 
227 224 cases of TB were reported in South Africa in 2017 (World Health Organisation, 
2018) and of these 7 700 were infected with a drug-resistant strain. The rise in drug 
resistance, HIV co-infection and the lack of effective vaccines escalates the TB burden in 
the world. 
Tuberculosis is the major cause of death among HIV-positive people (Gandhi et al., 
2006). The weakened immune system in these patients makes it more challenging to fight 
the TB infection and therefore leads to the high TB-related mortality among them. The 
growing TB epidemic is associated with increased HIV infection in sub-Saharan Africa 
(UNAIDS, 2017; Mohammed et al., 2018). Among the 10 million new cases of TB 
reported in 2017, 9 % were among HIV-positive people, with 72 % of these resided in 
Africa (World Health Organisation, 2018). Majority of the TB and HIV co-infected cases 
were found in the southern Africa region (Figure 1.1) in some parts exceeding 50 %. This 
ranks Africa as the highest region of HIV and TB co-infection globally. South Africa 
alone constituted 39 % of the global burden of HIV- associated TB (World Health 
Organisation, 2018). The combined burden of the TB and HIV epidemics remain a crucial 
public health concern in South Africa (Karim et al., 2009; Middelkoop et al., 2014; 
Gouden et al., 2018) and KwaZulu-Natal province has the highest number of TB-HIV co-
infection patients (Pietersen et al., 2014; Niehaus et al., 2015; Shah et al., 2017) with co-
infection rates exceeding 70 % (Shah et al., 2017). 
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Figure 1.1: A worldwide estimate of the prevalence of HIV-TB co-infection in 2017 
(World Health Organisation, 2018) 
 
In addition to the burden of TB-HIV co-infection, the rise in drug resistance poses a 
serious challenge to TB control programs in the world. Drug-resistant strains of M. 
tuberculosis include MDR and XDR strains. Multidrug-resistant strains are resistant to 
both isoniazid and rifampicin, which are the first-line drugs for anti-TB treatment, and 
XDR strains are resistant to rifampicin and isoniazid, plus resistance to any 
fluoroquinolone and any one of the three injectable drugs (amikacin, capreomycin and 
kanamycin) (World Health Organisation, 2018). Cases of infection with strains resistant 
to all the first-line and second-line anti-TB drugs available have been reported (Migliori 
et al., 2007; Velayati et al., 2009; Klopper et al., 2013). These strains are called totally 
drug-resistant strains. In 2017, an estimated caseload of 558 000 new cases of MDR-TB 
was reported globally, and this included 3.5 % of new cases and 18 % of previously 
treated cases (World Health Organisation, 2018). Fifty-four per cent of the total MDR-
TB cases reported globally were notified in Russia, China and India (Figure 1.2). An 
average of 8.5 % of the estimated MDR-TB cases had XDR-TB. An absolute number of 
10 800 cases of XDR-TB were reported, and a total of 230 000 deaths occurred among 
the drug-resistant TB cases. South Africa is the fourth amongst the five countries that 
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have reported the most significant number of XDR-TB cases with 747 cases (World 
Health Organisation, 2018). In South Africa, the highest burden of XDR-TB was reported 
in KwaZulu-Natal province with 1 027 cases diagnosed between 2011 and 2014 (Shah et 
al., 2017; Kapwata et al., 2017). 
 
 
Figure 1.2: A worldwide estimate of the incidence of drug-resistant TB in 2017 
(World Health Organisation, 2018) 
 
Pulmonary TB is more prevalent than extrapulmonary TB, with the former being the most 
common among HIV-infected people (Gouden et al., 2018). A compromised immune 
system is one of the principal risk factors leading to the development of extrapulmonary 
TB (Naing et al., 2013; Gouden et al., 2018), making young children and HIV-infected 
individuals more susceptible to this form of the disease (Cherian & Thomas, 2011). 
Extrapulmonary TB constitutes 15 – 20 % of all cases of TB globally (Chitra et al., 2017). 
An estimate of 50 % of patients with extrapulmonary TB has still concurrent pulmonary 
involvement and HIV co-infection (Herath & Lewis, 2014; Lee, 2015; Chitra et al., 2017). 
According to WHO, the global incidence of extrapulmonary TB was estimated to be 14 
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% in 2017 (World Health Organisation, 2018). The highest incidence occurred in the 
Eastern Mediterranean (24 %) and the lowest incidence in the Western Pacific region (8 
%) (Figure 1.3). Africa had the second highest incidence at 16 %, which is higher than 
the reported global incidence of 14 % (World Health Organisation, 2018). 
 
 
 
Figure 1.3: The global incidence of extrapulmonary TB in 2017 (World Health 
Organisation, 2018) 
 
1.2.2. Predominant Mycobacterium tuberculosis strain families in South Africa 
Molecular epidemiological studies of TB have enhanced our understanding of the 
diversity of the M. tuberculosis genotypes (Bos et al., 2014; Coscolla & Gagneux, 2014). 
Seven lineages of M. tuberculosis have been identified and linked with different 
geographic areas (Bos et al., 2014; Coscolla & Gagneux, 2014). Among these seven 
lineages, lineage 2 (East Asian) and 4 (Euro-American) are the most globally distributed 
and most virulent lineages when compared to the others (Coscolla & Gagneux, 2014). 
Figure 1.4 shows that lineage 2 (which includes the Beijing strain family) is predominant 
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in the Eastern Asia region, but also circulates in the Russia and Southern Africa regions. 
In South Africa, it is well established that there is a high level of diversity among M. 
tuberculosis strains. The Beijing, F15/LAM4/KZN (KZN), F28 and F11 genotypes were 
found to drive the burden of TB disease in the country (Streicher et al., 2004; Gandhi et 
al., 2006; Mlambo et al., 2008; Chihota et al., 2012; Kamudumuli et al., 2015). 
 
 
 
Figure 1.4: (A) Lineages of M. tuberculosis represented in colour, (B) the most 
geographically distributed lineages, (C) lineages with intermediate distribution, and 
(D) lineages with the least geographical distribution (Coscolla & Gagneux, 2014) 
 
The Beijing strain genotype is one of the main lineages identified to be distributed 
globally (Gagneux & Small, 2007). This genotype was described for the first time in 1995 
and was the first spreading M. tuberculosis strain to be found (van Soolingen et al., 1995). 
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It was described as the predominant genotype in Beijing, China, and was found to be 
distributed similarly in neighbouring countries, including Mongolia, Thailand and South 
Korea (van Soolingen et al., 1995). The lineage has been reported all over the world and 
also in cases associated with drug resistance in various settings (Frieden et al., 1993; 
Bifani et al., 1996; Bifani et al., 2002; Glynn et al., 2002; Brown et al., 2010), including 
in South Africa (Johnson et al., 2010). 
The first outbreak of MDR-TB caused by the Beijing strain occurred in the 1900s, in New 
York, in a population that had a high prevalence of HIV (Frieden et al., 1993; Bifani et 
al., 1996). In South Africa, MDR-TB was identified for the first time in the Western Cape 
Province in 1985, but information about the genotype from these isolates is not available 
(Streicher et al., 2004). Since then, MDR-TB and XDR-TB cases associated with the 
Beijing strain have been reported, predominantly in the Eastern and Western Cape 
provinces (Brown et al., 2010; Chihota et al., 2012; Klopper et al., 2013). This strain has 
been classified as the most successful M. tuberculosis strain family due to its worldwide 
distribution, together with its emergence of drug resistance (Hanekom et al., 2011). An 
association between the Beijing strain and extrapulmonary TB has been reported in past 
studies (Dale et al., 2005; Nicol et al., 2005; Maree et al., 2007; Caws et al., 2008; Click 
et al., 2012). However, these findings are contradictory as positive, negative, and no 
association between the Beijing strain and extrapulmonary TB has also been reported. 
The F15/LAM4/KZN (KZN) strain is the primary strain driving the epidemic of resistant 
TB in the KwaZulu-Natal province, in South Africa (Gandhi et al., 2014). Like the KZN 
strain, F15 is a strain family that is part of the Latino-American and Mediterranean (LAM) 
family, and its spoligotype pattern has similarities with the LAM4 sub-lineage (Filliol et 
al., 2002; Streicher et al., 2007). The KZN strain has been in existence in KwaZulu-Natal 
province as early as 1994, the same year in which the first MDR isolate of the strain was 
identified (Pillay & Sturm, 2007). The first XDR-TB case associated with the KZN strain 
was notified in 2001 in one patient (Pillay & Sturm, 2007), then followed by the largest 
XDR-TB outbreak that occurred in Tugela Ferry in 2005 (Gandhi et al., 2006). During 
this outbreak, 98 % of HIV co-infected patients died within an average of 16 days. The 
F15/LAM4/KZN genotype has developed into a family of closely related strains 
accompanied by progression from drug-susceptible to MDR then to XDR (Pillay & 
Sturm, 2007). The rapid spread of the KZN strain and the high mortality rate that occurred 
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during the 2005 Tugela Ferry outbreak implies increased virulence. The association 
between the KZN strain and affinity for extrapulmonary sites was reported in one study 
using osteoblasts (Sarkar et al., 2016). The study reported that the invasion capacity of 
strains increased with resistance level, with the KZN-XDR variant having the highest 
number of intracellular organisms when compared to other variants (Sarkar et al., 2016). 
The F28 and F11 strain families are two of the four strains that were identified in more 
than 70 % of drug-resistant TB cases in the Western Cape Province, South Africa 
(Streicher et al., 2004). The spoligotype pattern of the F28 family corresponds with the S 
sub-lineage (Filliol et al., 2002; Nguyen et al., 2003; Brudey et al., 2006; Streicher et al., 
2007) and that of the F11 family corresponds with the LAM3 sub-lineage (Filliol et al., 
2002; Streicher et al., 2007). It has been reported that the F28 strain is responsible for 9.7 
% of TB cases among patients from the urban communities in Cape Town (Richardson et 
al., 2002). Although the F28 genotype appears to be common in the Western Cape 
Province, comparison of the spoligotypes and IS6110-RFLP types in the international 
National Institute for Public Health and Environment (RIVM), Bilthoven, The 
Netherlands database suggests that this strain family may be more worldwide distributed 
than previously thought (Sarkar et al., 2016). This strain family was never reported from 
other parts of South Africa and other regions of Africa. According to Sarkar et al., (2016), 
the MDR F28 strain has a decreased affinity for osteoblasts (representing an 
extrapulmonary site) when compared to the MDR- and XDR-KZN strains, and the drug-
susceptible F11 strain (Sarkar et al., 2016). In the Western Cape Province, the F11/LAM3 
strain family is present in 21.4 % of all TB patients, suggesting that it is as much 
successful as the Beijing strain family which is responsible for 16.5 % cases (Streicher et 
al., 2004; Victor et al., 2004). Although the F11/LAM3 strain is predominant in the 
Western Cape, the strain has also been reported from other parts of South Africa (Mlambo 
et al., 2008; Chihota et al., 2012; Kamudumuli et al., 2015) and was also reported to be 
globally distributed (Victor et al., 2004). Findings from Sarkar et al., (2016) demonstrated 
the F11/LAM3 strain as the most invasive strain in osteoblasts (Sarkar et al., 2016), 
implying increased virulence in this extrapulmonary site. 
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1.2.3. Pathogenesis of tuberculosis 
Tuberculosis infection occurs when droplet nuclei containing M. tuberculosis bacilli, are 
expelled into the air from the lungs of a person infected with TB and inhaled by a healthy 
person (Torrelles & Schlesinger, 2017; Koul et al., 2011). In the classic pathogenesis 
model, after inhalation of the bacilli, they settle in the alveoli of the lung, where alveolar 
macrophages then phagocytose them. Recent findings indicate that the bacilli also invade 
alveolar epithelial cells, but not bronchiolar cells (Ashiru et al., 2010). The infection can 
either be eliminated by innate and adaptive immune responses or become an 
asymptomatic infection known as latent TB infection or develop into active disease. 
Innate and adaptive immune responses are initiated, following cytokine secretion and 
immune cell recruitment induced by pathogen recognition processes, to clear the 
pathogen from the infected site (Cantone et al., 2017). During latent TB infection, bacilli 
are surrounded but not completely eliminated, and infected individuals are asymptomatic 
upon initial infection (Kumar et al., 2011). This latent infection can last a lifetime, but a 
compromised immune system increases the risk of disease activation (Kumar et al., 
2011). Active TB develops in only 5 - 10 % of people with latent TB. This is referred to 
as reactivation disease, a term which refers to the reactivation of dormant bacilli, not to 
the second episode of disease. Active TB is characterised as an infection with signs of 
clinical disease. It develops when the host fails to develop an immune response that can 
control the initial infection (Gengenbacher & Kaufmann, 2012). 
Although the lung is the primary site of infection, M. tuberculosis can disseminate and 
also infect other parts of the body. Mycobacterium tuberculosis can initiate 
extrapulmonary TB by lymphatic or hematogenous dissemination of the bacilli from the 
lung to other organs of the body (Sharma et al., 2005; Golden & Vikram, 2005; Qin et 
al., 2015), including the CNS (meninges), lymph nodes, bones and joints, pleura, 
genitourinary tract, peritoneum and other abdominal organs (Golden & Vikram, 2005; 
Lee, 2015). The CNS is the most serious location where infection may result in meningitis 
or a brain tuberculoma, which is fatal in most cases (Golden & Vikram, 2005). 
Tuberculous meningitis is an essential manifestation of the disease in both infants and 
immunocompromised individuals. Central nervous system TB is a secondary infection 
resulting from the dissemination of infection from the lungs to the meninges and brain 
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parenchyma via the circulation (Donald et al., 2005; Rock et al., 2008; Be et al., 2009). 
Despite the protective properties of the BBB, it has been suggested that M. tuberculosis 
can pass through the BBB and invade the CNS as free bacilli. These findings are 
supported by studies that have illustrated the upregulation of a specific gene of M. 
tuberculosis associated with traversal of the BBB (Jain et al., 2006). However, the 
mechanisms by which M. tuberculosis evades the protective properties of the BBB remain 
understudied. Infection of the meninges, the formation of localised foci (Rich foci), 
followed by the release of bacilli into the subarachnoid space are first events 
characterising CNS-TB (Donald et al., 2005). When the bacilli are deposited in large 
numbers, tuberculous meningitis or formation of tuberculomas may occur, especially in 
infants or young children (Be et al., 2009). However, deposited bacilli may not induce an 
immune response in older children and adults. This may cause latent CNS disease, and 
when the bacilli are later recognised by the immune system or reactivated, the formation 
of tuberculomas in the CNS ensues (Be et al., 2009). These tuberculomas may then 
rupture into the cerebrospinal fluid, leading to severe inflammation and tuberculous 
meningitis. Tuberculous meningitis typically presents an insidious subacute course, and 
for most untreated patients, death ensues within five to eight weeks of the onset of illness 
(Ramirez-Lapausa et al., 2015). Figure 1.5 below illustrates the dissemination of 
pulmonary TB to extrapulmonary TB in the CNS. 
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Figure 1.5: Dissemination of TB from the lungs to the CNS (Be et al., 2009) 
 
1.2.3.1. Immune response to tuberculosis 
The human immune response consists of the innate and adaptive immune responses. 
Cooperation of both immune responses is required for the host to efficiently eliminate 
invading microbial pathogens (Smith, 2003; Dannenberg, 2006; Kawai & Akira, 2010). 
An innate immune response is a form of natural immunity whereby immune components, 
mainly complement, neutrophils and NK-cells, provide the first line of protection against 
an invading pathogen that the host has not encountered previously. This natural immunity 
is facilitated by macrophages and dendritic cells (DCs) resident at the site of infection 
following the recognition of M. tuberculosis bacilli (O’Garra et al., 2013). 
Pathogen recognition elicits chemokine and cytokine secretion resulting in immune cells 
recruitment and activation, initiating an immune response to clear the pathogen from the 
infected site (Roitt et al., 2002). Once the pathogen is recognised, the mycobacteria are 
engulfed by alveolar macrophages. These alveolar macrophages are considered to be the 
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first cellular element of the immune response (Chen et al., 2018). The ability of these 
cells to destroy ingested pathogens depends on their innate microbicidal capacity (Chen 
et al., 2008; O’Garra et al., 2013). Dendritic cells and neutrophils, as well as the 
pulmonary epithelial cells lining the alveoli also internalise the bacilli (Bermudez & 
Goodman, 1996; O’Garra et al., 2013). Studies report that M. tuberculosis is more likely 
to encounter alveolar macrophages than alveolar epithelial cells after inhalation of the 
bacilli (Cohen et al., 2018; Huang et al., 2018). However, the number of alveolar 
epithelial cells present in the alveolar space is high compared to the number of 
macrophages (Bermudez & Goodman, 1996; Chuquimia et al., 2012; Randall et al., 
2015). Therefore, the likelihood of the bacilli encountering an alveolar epithelial cell 
instead of a macrophage is higher (Bermudez & Goodman, 1996; Bermudez et al., 2002; 
Ashiru et al., 2010; Chuquimia et al., 2012; Randall et al., 2015). This initial interaction 
of M. tuberculosis with epithelial cells might result in chemokine secretion (Cantone et 
al., 2017), which recruit macrophages and neutrophils to the primary site of infection 
(Chuquimia et al., 2012). When strong enough, the innate immune response can eliminate 
the pathogen. However, if the bacilli survive via its mechanisms acquired to allow 
intracellular survival and proliferation, they continue to replicate actively in the 
macrophages and subsequently spread to adjacent cells and tissues (Wolf et al., 2008). 
The intracellular proliferation of the bacilli induces a robust inflammatory response in the 
macrophages, inducing production of cytokines like interleukin (IL)-1, IL-8, IL-12, 
interferon (INF)-γ and tumour necrosis factor (TNF)-α (Silva et al., 2012). An 
inflammatory response is essential for the host to control the infection (Smith, 2003). The 
inflammatory response results in the activation and recruitment of more macrophages 
from the circulation and other phagocytic cells (Torrelles & Schlesinger, 2017). 
Simultaneously, resident DCs in the lung engulf the bacilli or products derived from its 
intracellular proliferation, and the ongoing inflammatory signals promote DC migration 
from the lung to the draining lymph node, activating T cells of the adaptive immune 
system (Tian et al., 2005; Wolf et al., 2008). 
The adaptive immune system is extremely specific, as it is influenced by the immune 
system’s previous interaction with a pathogen, or its immunogenic components (antigens) 
(Vankayalapati & Barnes, 2009). It is mediated by T and B lymphocytes, facilitated by 
specific antigen receptors that are expressed on the surface of these cells, and its 
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immunological memory makes the adaptive response long-lasting. Following the 
recognition of the infected macrophages and migration of DCs to the draining lymph 
nodes, T cell activation and expansion occurs (Shi & Sugawara, 2013). T cells can be 
grouped into two subsets, T helper (Th) 1 and Th2, based on the cytokines they produce. 
T helper 1 cells play a significant role in defence against tuberculosis, and they suppress 
Th2 cells during tuberculosis (Shi & Sugawara, 2013). Th1 cells produce significant 
amounts of TNF-α and IFN-γ, which increases the microbicidal capacity of the infected 
macrophages, which eventually result in the intracellular killing of M. tuberculosis bacilli 
(O’Garra et al., 2013). The Th1 response, however, does not lead to complete elimination 
of the bacilli but the formation of granuloma. The granuloma attempts to "wall off" and 
restrict the growth of the bacilli by surrounding it with immune cells (Russell, 2007; 
Russell et al., 2009; Ramakrishnan, 2012; Mahamed et al., 2017). Live M. tuberculosis 
bacilli remain confined inside the granuloma, protected from the host immune response, 
often in a non-metabolically active state for a long time or most often for a lifetime. This 
state is called latent infection (Silva et al., 2012). Although granulomas contain the 
infection, they do not always succeed. They may progress to central necrosis and 
cavitation, promoting multiplication and dissemination of the pathogen into the airways, 
release of the M. tuberculosis into the environment and transmission of the infection to 
susceptible hosts (Russell, 2007; Barry et al., 2009; Russell et al., 2009; Ramakrishnan, 
2012; Mahamed et al., 2017). Failure of the granuloma to contain infection and 
reactivation of infection may result from events that weaken the host immune defences 
such as HIV infection (Kumar et al., 2011; Silva et al., 2012). 
Within the CNS, microglial cells are located in the brain parenchyma by the BBB and are 
the first line of defence against M. tuberculosis (Spanos et al., 2015). Following infection 
with M. tuberculosis, activated microglia release proinflammatory cytokines that 
contribute towards defence against the pathogen (Rock et al., 2005; Yang et al., 2007; 
Hernandez Pando et al., 2010; Be et al., 2011; Cannas et al., 2011). Some of the 
chemokines and cytokines reported in in vitro studies include TNF-α, IL-6 and IL-1β 
(Rock et al., 2005; Cannas et al., 2011). Similar cytokines were reported in in vivo studies 
(Hernandez Pando et al., 2010; Be et al., 2011; Francisco et al., 2015). 
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1.2.4. Interaction between epithelial cells and Mycobacterium tuberculosis 
An important component of the mucosal barrier and innate immune response of the lung 
that protects it against respiratory pathogens is the alveolar epithelium. This epithelium 
is made up of type I and II pneumocytes, providing a barrier function that detects 
pathogens through pattern recognition receptors, and secretion of surfactant proteins, 
chemotactic factors, cytokines and antimicrobial molecules (Lin et al., 1998; Chuquimia 
et al., 2013). The focus of most studies is to investigate the role of alveolar macrophages 
and other professional phagocytes such as neutrophils, dendritic cells and monocytes in 
the development of M. tuberculosis infection. However, increasing evidence implicates 
the type II alveolar epithelial cells in both host cell defence and bacterial pathogenicity 
(Chuquimia et al., 2012; Ryndak et al., 2015). The logic for studying the interaction 
between mycobacteria and epithelial cells in addition to the ability of M. tuberculosis to 
infect these cell types is that the alveoli of the lung are made up of over 95 % epithelial 
cells (Bermudez & Goodman, 1996; Chuquimia et al., 2012). Therefore, it is more likely 
that M. tuberculosis will interact with epithelial cell first before encountering any other 
cell (Ashiru et al., 2010; Chuquimia et al., 2012). The interaction between M. tuberculosis 
and epithelial cells may result in the activation of macrophages and could facilitate their 
migration to the site of infection. 
The first study of M. tuberculosis-epithelial cell interactions established the use of the 
immortalised human alveolar epithelial cell line A549 (McDonough & Kress, 1995). This 
model proved to be suitable for examining the interaction of M. tuberculosis with the 
alveolar epithelium. This study revealed two significant findings. First, M. tuberculosis 
can adhere to and invade respiratory epithelial cells with virulent strains noted to be more 
cytotoxic and second, the intracellular passage of M. tuberculosis within macrophages 
enhances the association between M. tuberculosis and epithelial cells (McDonough & 
Kress, 1995). Subsequent to this study, Bermudez and Goodman (1996) reported on 
findings that demonstrate the intracellular replication of M. tuberculosis within A549 
cells (Bermudez & Goodman, 1996). It was observed that efficient invasion and 
intracellular replication in alveolar epithelial cells is possible (Bermudez & Goodman, 
1996). Other studies have also supported this theory by comparing the intracellular 
multiplication of M. tuberculosis in cultures of macrophages and bronchial cells (Mehta 
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et al., 1995; Ashiru et al., 2010). These comparison studies demonstrated that the rate of 
intracellular replication of M. tuberculosis was significantly higher in alveolar epithelial 
cells than in the other cell types (Mehta et al., 1995; Ashiru et al., 2010). 
During the progression of TB, M. tuberculosis destructs and disrupts the alveolar 
epithelium to allow the bacilli to gain passage back into the airways to enable 
dissemination to a new host. Based on this, several studies were initiated to demonstrate 
whether the A549 model could be used to reproduce this phenomenon in vitro. 
Cytotoxicity of epithelial cells is a result from infection with virulent M. tuberculosis 
strains (McDonough & Kress, 1995) and this cytotoxicity is caused by cellular necrosis 
(Dobos et al., 2000; Ashiru & Sturm, 2015). Dobos et al., (2000) reported that the cellular 
necrosis in A549 monolayers did not occur due to intracellular or extracellular growth but 
as a result of A549 cell membrane permeation (Dobos et al., 2000). This necrosis required 
infection with viable M. tuberculosis, suggesting that the observed cell toxicity was due 
to a bacterial factor(s) (Dobos et al., 2000). It was further demonstrated that cytotoxicity 
levels in alveolar epithelial cells are significantly higher in virulent strains grown under 
anaerobic conditions (Ashiru & Sturm, 2015). 
 
Studies have enriched our understanding of mechanisms used by M. tuberculosis to pass 
through epithelial barriers during infection using in vitro models of mucosal barriers 
(Birkness et al., 1999; Bermudez et al., 2002; Ryndak et al., 2016). Birkness et al., (1999) 
devised the first in vitro model of an alveolar epithelium (Birkness et al., 1999). A 
polarised bilayer of epithelial and endothelial cells was assembled and used to measure 
the ability of M. tuberculosis to cross the bilayer. Using this model, it was observed that 
large numbers of bacteria adhered to and invaded the epithelial cells and that a small 
percentage of the inoculum translocated the bilayer (Birkness et al., 1999). Furthermore, 
the migration of peripheral blood mononuclear cells through the bilayer to the upper 
chamber was observed when these cells were added to the lower chamber. These cells 
were seen associated with M. tuberculosis on the epithelial cells (Birkness et al., 1999). 
Similarly, Bermudez et al., (2002) confirmed the previously observed translocation of M. 
tuberculosis across the bilayer (Bermudez et al., 2002). In this study, bacteria recovered 
from infected A549 cells or macrophages was increased, again demonstrating that an 
invasive phenotype emerges following intracellular passage (Bermudez et al., 2002). 
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Furthermore, the addition of infected and uninfected monocytes to the bilayer 
demonstrated efficiency in the translocation of infected monocytes than the uninfected 
ones (Bermudez et al., 2002). Additionally, infection of the A549 cells in the bilayer with 
M. tuberculosis also increased monocyte translocation (Bermudez et al., 2002). Although 
these studies have demonstrated that monocytes serve as a transport vehiculum for the 
dissemination of M. tuberculosis through the epithelial-endothelial bilayer, other studies 
have proven that the bacilli are also able to migrate independently (Pethe et al., 2001; 
Ryndak et al., 2016). These results strongly suggest that M. tuberculosis could exploit 
epithelial cells as protection against immune responses in which they also expand and 
acquire a phenotype that enables rapid dissemination during primary infection. This 
ability to pass and damage the epithelial barrier may, therefore, contribute to the 
dissemination of bacilli from the lungs to other organs. 
 
1.2.5. Interaction between glial cells and Mycobacterium tuberculosis 
Glial cells, along with neurons, form the CNS. Glial cells support and nourish neurons, 
and isolate and shield the nervous tissues against injuries from foreign bodies (Cannas et 
al., 2011). Microglia, one of the glial cells, are the inhabitant macrophages of the brain 
parenchyma, and they share numerous, if not all, characteristics of macrophages in other 
tissues. Such characteristics include the production of different cytokines and chemokines 
induced by several stimuli (Curto et al., 2004; Cannas et al., 2011) such as M. tuberculosis 
infection. For M. tuberculosis to reach the CNS, it must first cross the BBB. Mechanisms 
involved in this process are not well studied. A study by Jain et al., (2006) developed an 
in vitro model of the BBB which was used to identify microbial components of M. 
tuberculosis associated with invasion and traversal of the BBB during CNS-TB 
pathogenesis (Jain et al., 2006). In this study, virulent M. tuberculosis strains were able 
to invade and traverse the endothelial cell monolayer more efficiently than non-
pathogenic strains. This in vitro model used human brain microvascular endothelial cells, 
which makes up the BBB but did not include cells found in the brain side of the BBB. 
Therefore, the role played by these cells in defence against entry into the brain 
parenchyma is not well studied. 
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In vitro studies have established microglial cells as the principal host cells of M. 
tuberculosis. Invasion of these cells results in the activation and release of 
proinflammatory cytokines such as TNF-α and IL-6 (Rock et al., 2005; Cannas et al., 
2011). Following infection of human microglia and astrocytes with M. tuberculosis in 
vitro, Rock et al., (2005) observed an invasion of 76 % and 15 % respectively (Rock et 
al., 2005). Furthermore, microglia released robust amounts of numerous cytokines and 
chemokines than astrocytes (Rock et al., 2005), implying that microglia play an essential 
role in the pathogenesis of CNS-TB. In another study, it was demonstrated that non-
invasive lysates of M. tuberculosis induce a similar inflammatory response and reactive 
oxygen species (ROS) generation as in infection with live M. tuberculosis in microglial 
cell lines (Yang et al., 2007). In addition, primary mixed glial cells (astrocyte-enriched 
cultures) induced less robust cytokine production and ROS generation compared to the 
microglial cell lines (Yang et al., 2007). These findings support previous findings that M. 
tuberculosis selectively infects human microglia rather than astrocytes (Rock et al., 
2005). These studies have established that the activation of microglial cells by M. 
tuberculosis occurs through cytokine and chemokine responses, and protein and gene 
expression studies support these findings (Qin et al., 2015). Similar as in vitro studies, 
animal models have also demonstrated that activated microglia are recruited to TB lesions 
and are noted to have intracellular bacilli (Hernandez Pando et al., 2010; Be et al., 2011; 
Francisco et al., 2015; Tucker et al., 2016). These in vitro and in vivo studies have 
sufficiently explored host-microbe interactions by targeting crucial inflammatory 
pathways involved in CNS-TB pathogenesis. 
Past studies have indicated that the differences in M. tuberculosis genotypes can 
contribute to variations in host immune response, virulence and clinical outcome of 
disease (Caws et al., 2008; Click et al., 2012; Sarkar et al., 2016). Additionally, it has 
been demonstrated that dissemination and pathology due to strain specificity is possible, 
suggesting that virulence factors might enable invasion and survival of M. tuberculosis 
in the CNS (Hernandez Pando et al., 2010; Be et al., 2011). When bacterial and host 
genotypes, including their interaction, were compared across two large groups of 
Vietnamese adults with meningeal or pulmonary TB, Caws et al., (2008) demonstrated 
an association between M. tuberculosis genotype and disease outcome (Caws et al., 
2008). Disease caused by the Euro-American lineage was less likely to be meningeal than 
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pulmonary, suggesting that this lineage may be less capable of extrapulmonary 
dissemination in this Vietnamese study population (Caws et al., 2008). Data from this 
study also suggest that specific genes found in hosts are associated with meningeal TB 
caused by the East Asian (Beijing) genotype (Caws et al., 2008). In contrast, when the 
East Asian/Beijing lineage was compared with three other lineages (East-African Indian, 
Euro-American and Indo-Oceanic lineages), the East Asian lineage was relatively less 
associated with extrapulmonary TB rather than pulmonary TB (Click et al., 2012). 
Previous studies have also reported a positive association between the East Asian lineage 
with pulmonary TB (Dale et al., 2005). Although the above findings prove that there is 
an association between M. tuberculosis genotype and disease outcome, studies from the 
Western Cape Province in South Africa found no association between M. tuberculosis 
genotype and clinical presentation or disease outcome (Nicol et al., 2005; Maree et al., 
2007). 
Microglia phagocytose virulent M. tuberculosis more rapidly and efficiently than less 
virulent strains (Curto et al., 2004). It is in these cells where M. tuberculosis bacilli retain 
a potential to proliferate, therefore providing a conducive environment for persistence 
and mechanism for subsequent reactivation should a state of immunosuppression be 
acquired (Curto et al., 2004; Cannas et al., 2011). Based on findings that the invasion 
capacity of the KZN strain increases with the level of resistance when compared to the 
F28 (MDR) and F11 (susceptible) strains (Sarkar et al., 2016), and that M. tuberculosis 
strains are able to migrate across in vitro alveolar barriers (Ryndak et al., 2016), it is of 
importance to determine how these strains compare in terms of their ability to cross the 
alveolar barrier and subsequently invade extrapulmonary sites like the CNS. 
 
1.3. Significance of this study 
Studies have adequately explored the association between M. tuberculosis strains and site 
of extrapulmonary TB. However, these studies investigated mostly the H37Rv laboratory 
strain and the CDC 1551 clinical strain, suggesting a lack of strain diversity when 
investigating host-microbe interaction in the development of extrapulmonary TB. 
Additionally, most of the in vivo studies have used intra-cerebral injection models which 
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do not imitate the natural CNS disease occurrence which is caused by hematogenous 
dissemination of M. tuberculosis from the lung, followed by the invasion of the CNS. A 
previous study in our Department has reported an association between different M. 
tuberculosis strains and tropism for osteoblasts. Therefore, we extended this study and 
compared the ability of the same strains to translocate the alveolar epithelial cell barrier 
and the subsequent invasion of microglial cells. These findings may contribute to the 
growing body of knowledge on CNS-TB pathogenesis and associated strain resistance 
profile. 
 
1.4. Aim of this study 
To determine and compare the transmigration of F15/LAM4/KZN, Beijing, F28 and F11 
strain families of M. tuberculosis across an in vitro alveolar epithelial cell barrier and 
their affinity for microglial cells. 
 
1.5. Objectives of this study 
i. To co-culture human alveolar epithelial cells and human microglial cells in a 
transwell system. 
ii. To infect the alveolar epithelial cells with F15/LAM4/KZN, Beijing, F28 and F11 
strains. 
iii. To analyse the transmigration of these strains across the alveolar epithelial cell 
monolayer into the microglial cell monolayer. 
iv. To determine the intracellular multiplication of these strains in microglial cells. 
 
1.6. Study design 
A human microglial cell line was cultured in a 24-well tissue culture plate, then infected 
with different M. tuberculosis isolates for 24 hours. Following incubation, the cells were 
lysed and plated on Middlebrook 7H11 agar plates to count the number of colony-forming 
units (CFU) per mL (CFU/mL). The CFUs were counted after three weeks and analysed. 
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A co-culture of human alveolar epithelial cells and human microglial cells was developed 
by growing A549 epithelial cells on transwell insert membranes and M059K glial cells 
in the wells of the transwell plate. The A549 cells were inoculated with various strains of 
M. tuberculosis for 48 hours. The spent culture media was harvested and plated on 
Middlebrook 7H11 agar plates to perform a CFU count, after three weeks, in order to 
analyse the ability of the various M. tuberculosis strains to transmigrate the A549 
epithelial cell monolayer. Following which, the M059K glial cell monolayers were lysed 
and also plated on Middlebrook 7H11 agar plates to perform a CFU count to further 
evaluate the ability of the strains to invade the glial cell monolayer following 
transmigration of an alveolar epithelial cell monolayer. 
 
1.7. Dissertation structure 
This dissertation is written in the traditional format, as accepted by the University of 
KwaZulu-Natal, comprising of four chapters. Chapter one contains the introduction and 
literature review. Chapter two details the materials and methods employed for the 
experimental procedures used in this study. Chapter three contains the results obtained, 
and chapter four comprises of the discussion, which examines the outcomes in the context 
of what has been published about this topic, limitations, conclusions drawn, as well as 
recommendations for future studies. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Ethics approval 
The study’s ethics approval was acquired from the Biomedical Research Ethics 
Committee (BREC), University of KwaZulu-Natal (Reference number: BE301/17). 
 
2.2. Growth of Mycobacterium tuberculosis strains 
All experiments with M. tuberculosis were conducted in a Biosafety Level II Laboratory 
at the Department of Medical Microbiology, University of KwaZulu-Natal. An N95 mask 
(3M Health Care, St. Paul, Minnesota, USA) and powder-free latex gloves were worn at 
all times. The M. tuberculosis strains were recovered from the culture collection of the 
Department. These included three strains belonging to the F15/LAM4/KZN (KZN) 
family, two strains to the Beijing family and one strain each to the F11 family and the 
F28 family. The laboratory strain H37Rv (ATCC 27294) was used as a reference strain. 
Table 2.1 shows the drug susceptibility and genotype profiles of the strains used in this 
study. Multidrug-resistance (MDR) was described as resistance to both isoniazid and 
rifampicin, which are the major first-line drugs used against TB, and extensive drug 
resistance (XDR) as resistance to rifampicin and isoniazid, plus resistance to any 
fluoroquinolone and any one of the three injectable drugs (capreomycin, kanamycin, and 
amikacin) (World Health Organisation, 2018). 
The isolates were retrieved from the – 70 °C freezer and thawed at room temperature. 
Following this, 100 µL of the suspension of each strain was inoculated in 10 mL of 
Middlebrook 7H9 broth (Difco Laboratories, Becton, Dickinson and Company, Sparks, 
USA), supplemented with 10 % of a mixture of oleic acid, albumin, dextrose, catalase 
(OADC) (Becton, Dickinson and Company, Sparks, USA) and 0.2 % glycerol (Rochelle 
Chemicals, Johannesburg, South Africa). The broth cultures were incubated at 37 °C in a 
shaking incubator until an optical density of 1.0 measured at a wavelength of 600 nm 
(OD600nm) was reached. The H37Rv laboratory strain, MODS 688 and MODS 388 strains 
reached an OD600nm of 1.0 at day 7 post inoculation while the TF 832, TF 44949 and 
V4207 strains reached OD600nm of 1.0 at day 8. The TF 1516 and R4933 reached OD600nm 
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1.0 at day 10 after inoculation into the Middlebrook 7H9 broth.  The cultures were 
subsequently subcultured on Middlebrook non-selective 7H11 (Difco Laboratories, 
Becton, Dickinson and Company, Sparks, USA) agar plates supplemented with 10 % 
OADC and 0.5 % glycerol (enriched Middlebrook agar). The plates were sealed with 
CO2-permeable plastic bags and incubated at 37 °C for three weeks. 
 
Table 2.1: Strains of Mycobacterium tuberculosis used in the study and their 
susceptibility profiles 
Strain number Mycobacterium 
tuberculosis strain 
family 
Resistant to: Susceptibility 
classification 
TF 1516 Beijing - Susceptible 
R4933 Beijing I, R, E, P, S, Eth, A, C, K, 
O 
XDR 
V4207 F15/LAM4/KZN - Susceptible 
MODS 688 F15/LAM4/KZN I, R, E, P MDR 
MODS 388 F15/LAM4/KZN I, R, E, P, S, Eth, A, C, K, 
O 
XDR 
TF 44949 F28 I, R, E, P MDR 
TF 832 F11/LAM3 - Susceptible 
 I isoniazid, R rifampicin, E ethambutol, P pyrazinamide, S streptomycin, Eth 
ethionamide, A amikacin, C capreomycin, K kanamycin, O ofloxacin, XDR extensively 
drug-resistant, MDR multidrug-resistant 
 
2.2.1. Inoculum preparation 
A loop full of M. tuberculosis culture grown on enriched Middlebrook 7H11 agar plate 
was harvested using a disposable plastic loop. To prepare bacterial single-cell 
suspensions, colonies were harvested into tubes containing six sterile glass beads 
(Associated Chemical Enterprises, Johannesburg, South Africa) and 6 mL of phosphate-
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buffered saline (PBS), pH 7.3 (Oxoid, Basingstoke Hampshire, England). To ensure that 
bacterial clumps are disrupted, the harvested bacteria were smeared carefully against the 
side of the tube before introduction into the fluid. The suspension was centrifuged at 3000 
x g for 20 minutes and resuspended in complete growth DMEM: F12 media. The 
suspension was subsequently vortexed for 5 minutes and after that allowed to stand for a 
further 15 minutes to allow the larger bacterial clumps to settle. The top 4 mL of the 
bacterial suspension was aspirated and transferred into a sterile tube. This aspirated 
suspension was subsequently passed four times through a sterile 25-gauge needle 
(Avacare Health, South Africa) followed by filtration through a 5.0 µm Millipore (Millex) 
filter (Merck Millipore, Tullagreen, Ireland). The measured OD600nm was used to 
standardise the suspensions. The suspension of each bacterial strain was diluted to obtain 
the target concentration of 1 X 107 bacteria/mL. From the suspensions, 10-fold serial 
dilutions were made in PBS, pH 7.3, and aliquots of 100 µL of each dilution were cultured 
on enriched Middlebrook 7H11 agar plates, in triplicate, to verify the number of colony-
forming units (CFU) per mL (CFU/mL). These plates were sealed with CO2-permeable 
plastic bags and incubated in a 5 % CO2 incubator at 37 °C for three weeks. 
 
2.3. Culture of cell lines 
Two types of cell lines were used in this study; human type II alveolar epithelial cell line 
A549 (ATCC CCL-185) and human glial cell line M059K (ATCC CRL-2365). Both cell 
lines were maintained under the same conditions, in 5 % CO2 in a humidified atmosphere 
at 37 °C. The medium was changed every 2 or 3 days unless stated otherwise. 
The A549 cells were cultured in Eagle’s Minimum Essential Medium (EMEM) (Lonza, 
Walkersville, USA) with 2 mM L-glutamine, 25 mM HEPES and 10 % fetal bovine serum 
(FBS) (Biowest, Nuaillé, France) added to the media. The M059K cells were cultured in 
a mix of equal amounts (ratio 1:1 v/v) of Dulbecco’s Modified Eagle’s Medium and 
Ham’s F12 medium (DMEM: F12) (Lonza, Walkersville, USA) containing 2.5 mM L-
glutamine, 15 mM HEPES and 10 % FBS per 500 mL. 
Both cell lines were subcultured when 80 – 90 % confluency was reached. The cells were 
washed three times with 10 mL of warm PBS, pH 7.3. This was followed by addition of 
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2 mL of a trypsin-versene mixture (Lonza, Walkersville, USA). The trypsin-versene 
mixture contains 0.5 g/L trypsin and 0.2 g/L versene (EDTA). Cells were incubated with 
the trypsin-versene at 37 °C for 3 – 10 minutes, depending on the cell type. After 
incubation cells were observed under an inverted microscope to check if they were 
detached from the flask. Two mL of FBS was then added to the culture flask to inactivate 
trypsin. The trypsinised cells were transferred to a 15 mL centrifuge tube and counted to 
determine the number of viable cells. The desired concentration of viable cells per cm2 
was resuspended in new flasks containing an appropriate aliquot of the complete growth 
medium appropriate for each cell line. 
The Trypan Blue Exclusion assay was used to determine the number of viable cells. In a 
Trypan Blue Exclusion assay, viable cells are distinguished by the ability to exclude the 
trypan blue dye due to their intact cell membrane, whereas the dye passes the cell 
membrane of non-viable cells. Viable cells appear clear and non-viable cells appear blue 
under a light microscope. A cell count was performed before seeding cells for infection 
experiments. To perform a cell count, 20 µL of trypsinised cell suspension and 20 µL of 
a 4 % Trypan Blue (Lonza, Walkersville, USA) dye were mixed in an Eppendorf tube, 
then 10 µL of the mixture was filled into a Neubauer haemocytometer chamber (Figure 
2.1). A Neubauer haemocytometer chamber has nine large squares. The four large squares 
at the corners, made up of a set of 16 small squares, were used to count viable cells. Viable 
cells located within each of the four large squares were counted under a light microscope. 
Cells located on the left and top lines of each square were included in the count, whereas 
those found on the right and bottom lines were excluded. Cell number was calculated 
using the following formula: 
 
Total no of cells (cells per mL) =
no. of cells
no. of squares
 × dilution factor × 104 
 
Where no. of cells is the number of viable cells counted within the four large squares, no. 
of squares represent the four large squares, and the dilution factor is the volume of cell 
suspension diluted with trypan blue dye that was added to the haemocytometer. 
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Figure 2.1: Neubauer haemocytometer chamber 
 
2.4. Co-culture of A549 and M059K cell lines 
Co-culture of cell monolayers was set up in 24-well plates (Costar, Corning-Incorporated, 
Kennebunk, USA) with transwell permeable supports (Costar, Corning-Incorporated, 
Kennebunk, USA) with a membrane pore size of 3.0 µm. The cells were harvested (2.3.) 
and counted (2.3.). An amount of 2 X 104 cells/mL of the A549 cell suspension was 
seeded onto the insert’s membrane and complete growth DMEM: F12 medium was added 
to the insert to a final volume of 200 µL. Starting from 24 hours after seeding the A549 
cells, the transmembrane electrical resistance (TER) of the monolayers in three different 
wells was monitored daily using a MilliCell ERS Volt/Ohm meter (EMD Millipore 
Corporation, Billerica, USA). Cells were incubated till stabilisation of the TER was 
reached. Inserts without cells were included as controls. 
A separate 24-well plate was used to seed 1 mL of 1 X 105 M059K viable cells. The cells 
reached confluency three days after seeding the A549 cells. On the day of infection, the 
inserts seeded with the A549 cells were placed in the 24-well plates seeded with M059K 
cells to establish the A549/M059K cell co-culture model. The model is shown in Figure 
2.2. 
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Figure 2.2: The A549/M059K cell co-culture model 
 
2.5. Infection of M059K cells with Mycobacterium tuberculosis 
Multiplication of M. tuberculosis in M059K glial cells was conducted as described before 
for osteoblasts (Sarkar et al., 2016). Confluent monolayers of M059K cells were washed 
three times with warm PBS, pH 7.3. Following the wash step, 1 mL of DMEM: F12 
supplemented with 10 % FBS was added to each well. The cells were then infected with 
the single-cell suspensions of each M. tuberculosis strain, in triplicate wells, at a 
multiplicity of infection (MOI) of 10 bacteria per glial cell. The cells were incubated for 
2 hours at 37 °C in a 5 % CO2 atmosphere. 
After 2 hours of incubation, infected cells were washed three times with warm PBS, pH 
7.3, and an aminoglycoside protection assay was performed to kill remaining non-
adherent extracellular bacteria. To carry out the aminoglycoside protection assay, 1 mL 
of complete DMEM: F12 media containing 200 µg/mL of amikacin (Sigma-Aldrich, St. 
Louis, USA) was added to the infected monolayers and incubated for 1 hour at 37 °C in 
a 5 % CO2 atmosphere. Afterwards, the media was removed, cultured on enriched 
Middlebrook 7H11 agar plates in triplicate and incubated for three weeks at 37 °C in a 5 
% CO2 atmosphere to check the removal of extracellular bacteria. To remove the 
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amikacin, cells were washed three times with warm PBS, pH 7.3. One mL of complete 
DMEM: F12 media was added to the cells and then further incubated for 24 and 48 hours. 
After the indicated time points, cells were washed three times with warm PBS, pH 7.3, 
and then lysed with 1 mL of 0.1 % Triton X-100 (Sigma-Aldrich, St. Louis, USA) for 20 
minutes at 37 °C. Lysates were 10-fold serially diluted, and 100 µL aliquots were cultured 
on enriched Middlebrook 7H11 agar plates for CFU count as described in 2.2.1 above. 
The inoculated Middlebrook 7H11 plates were sealed with CO2-permeable plastic bags 
and incubated in a 5 % CO2 incubator at 37 °C for three weeks. The obtained colony 
counts were used to determine the number of bacteria located within the M059K glial 
cells. The number of intracellular bacteria was expressed as a percentage of the inoculum 
using the following formula: 
 
Percent invasion =
CFU of intracellular bacteria
CFU of inoculum 
× 100 
 
 
2.6. Migration experiments 
A549 epithelial cells were infected at an MOI of 10 bacteria per epithelial cell. Before 
infection, the monolayers of both A549 and M059K cells were washed three times with 
warm PBS, pH 7.3. One mL of DMEM: F12 media supplemented with 10 % FBS was 
added to wells seeded with M059K cells and 200 µL of the bacterial suspension (~ 107 
bacteria) of each M. tuberculosis strain was added into the inserts above the A549 
monolayer. This was done in triplicate. After adding the bacterial suspensions, cells were 
incubated at 37 °C in a 5 % CO2 atmosphere. 
At 24 and 48 hours after incubation, inserts were removed from the wells and media from 
the space between the insert and M059K cells was harvested. Six tenfold serial dilutions 
were made of the harvested media in Middlebrook 7H9 broth, and 100 µL aliquots were 
cultured on enriched Middlebrook 7H11 agar plates. These plates were sealed with CO2-
permeable plastic bags and incubated in a 5 % CO2 incubator at 37 °C for three weeks. 
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Plates with an estimated colony number between 20 and 200 were used for counting to 
establish the CFU count per mL in undiluted media by multiplying the number of counted 
colonies with the dilution factor. The M059K monolayers were then washed with warm 
PBS, pH 7.3, three times to remove remaining media and non-adherent extracellular 
bacteria. Washed monolayers were lysed with 1 mL of 0.1 % Triton X-100 for 20 minutes 
at 37 °C. Lysates were serially diluted, and 100 µL aliquots were cultured on enriched 
Middlebrook 7H11 agar plates for CFU count as described in 2.2.1 above. The obtained 
colony counts were used to determine the percentage of transepithelial migration of 
bacteria as well as the combined percent adhesion and invasion of the M059K glial cells. 
The following formulas were used: 
 
Percent transmigration
=
(CFU of bacteria in media + CFU of adhered bacteria)
CFU added to insert
× 100 
 
Percent adhesion =
no. of adhered bacteria
no. of transmigrated bacteria 
× 100 
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CHAPTER 3: RESULTS 
Statistical analysis 
Statistical Package for the Social Sciences (SPSS) software (version 25) and Microsoft 
Excel were used to analyse data. Statistical analysis was done using Kruskal-Wallis (Non-
parametic ANOVA) Test followed by Dunn’s Multiple Comparisons Test. A p-value < 
0.05 was considered statistically significant. 
 
3.1. Co-culture of A549/M059K cell model 
To examine whether M. tuberculosis transmigrates through a polarised intact A549 
alveolar epithelial cell monolayer and subsequently adheres to and invade M059K glial 
cells, A549 and M059K cells were grown in transwell plates with A549 on the transwell 
membrane and M059K in the bottom of the well as described in 2.3. The structural 
integrity of the A549 monolayer was determined by measurement of the TER between 
the upper and lower chamber of the A549 cell-seeded transwell plates. The A549 
epithelial cell layer was observed as a single cell monolayer by microscopy. As shown in 
Figure 3.1 below, the TER of the A549 cells increased from day 1 to day 4, followed by 
stabilisation until day 6. The TER decreased on day 7, suggesting that there was damage 
or loss of structural integrity of the A549 cell monolayer. The stabilised A549 cell 
monolayer grown for six days was used for the transmigration assay. The confluent 
M059K glial cell monolayers, confirmed by microscopic observation, reached confluency 
three days after seeding. 
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Figure 3.1: Daily measurements of the TER (Ω.cm²) of A549 epithelial cell 
monolayer monitored in triplicate wells of a transwell plate. Results represent the 
mean TER (Ω.cm²) of three independent experiments performed in triplicate. 
 
3.2. Invasion of M059K glial cells by Mycobacterium tuberculosis strains 
To determine whether the extensively drug-resistant F15/LAM4/KZN (KZN-XDR), 
multidrug-resistant F15/LAM4/KZN (KZN-MDR), drug-susceptible F15/LAM4/KZN 
(KZN-S), extensively drug-resistant Beijing (Beijing-XDR), drug-susceptible Beijing 
(Beijing-S), drug-susceptible F11 (F11-S) and multidrug-resistant F28 (F28-MDR) 
strains of M. tuberculosis invade glial cells, glial cells were infected with each strain and 
incubated for 24 hours after which the extracellular bacteria were removed (2.5). The 
7H11 agar plates that were inoculated with the discarded media following the amikacin 
protection assay had no growth (2.5), confirming that only internalised bacilli were 
reported. Figure 3.2 shows the invasion rates of the different strains. The laboratory 
H37Rv strain invaded the M059K glial cells at a rate of 8 %. There was no significant 
difference in invasion rate between the KZN-XDR and F28-MDR strains and the H37Rv 
strain (p = 0.28 and p = 0.10, respectively). However, there was a significant difference 
in invasion rate between the KZN-S (p < 0.001), F11-S (p = 0.0001), Beijing-XDR (p = 
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0.0041), KZN-MDR (p = 0.0202) and Beijing-S (p = 0.0489) strains and the H37Rv 
strain. 
 
 
Figure 3.2: Percent invasion of M059K glial cells by different M. tuberculosis strains 
after 24 hours of incubation. 
 
3.3. Transepithelial migration and subsequent adhesion and invasion of M059K glial cells by 
different strains of M. tuberculosis 
All the M. tuberculosis strains used in the study were able to migrate through the A549 
epithelial cell monolayer and subsequently adhere to and invade the M059K glial cells. 
The transmigrations of the KZN-XDR, KZN-MDR, KZN-S, Beijing-XDR, Beijing-S, 
F11-S and F28-MDR strains were evaluated in comparison with the H37Rv laboratory 
strain. Figure 3.3.1 shows the percent transmigration of the different strains over 24 and 
48 hours. At the 24-hour time point, the Beijing-XDR strain displayed the highest percent 
transmigration when compared to all other strains, followed by the KZN-S and the KZN-
XDR strains. However, when compared to H37Rv, statistically significant differences 
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were observed for the Beijing-XDR (p = 0.004) and KZN-S (p = 0.03) strains only. 
Although the F11-S, KZN-MDR and F28-MDR strains demonstrated neglectable 
transmigration rates, those of the F11-S and KZN-MDR strains were significantly 
different from that of the H37Rv laboratory strain (p = 0.0374 and p = 0.004, 
respectively). There was no significant difference in transmigration rate between the F28-
MDR (p = 0.15) and KZN-XDR (p = 0.16) strains and the H37Rv strain. No cells of the 
Beijing-S strain were found in the basolateral fluid at the 24-hour time point. 
After 48 hours of incubation, the transmigration rate of the H37Rv strain remained stable. 
In contrast, there was a decrease in the number of bacteria of the KZN-S and Beijing-
XDR strains. The KZN-XDR strain was the only strain which displayed a slight increase 
in the number of bacteria. Although the Beijing-XDR strain showed a decrease in the 
percentage of the transmigrated organisms at this time point, its transmigration rate 
remained the highest amongst all other strains. The transmigration of KZN-MDR, F11-S 
and F28-MDR did not increase while the Beijing-S strain still did not show any sign of 
transmigration. The KZN-S and F11-S strains did not show a statistically significant 
difference when compared to the H37Rv (p = 0.18). 
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Figure 3.3.1: Percent transepithelial migration of different M. tuberculosis strains. 
Blue bars represent the 24-hour time point, and orange bars represent the 48-hour 
time point. 
 
Figure 3.3.2 shows the combined adhesion and invasion of the M059K glial cells after 
migration through the A549 epithelial cell monolayer. All M. tuberculosis strains that did 
transmigrate retained their affinity for glial cells. The results were similar for all strains, 
with an increase in the percent adhesion and invasion from 24 hours to 48 hours of 
incubation. At 24 hours, the H37Rv laboratory strain was found to adhere to and invade 
glial cells at a rate of 7 %. The Beijing-XDR strain displayed a significantly high adhesion 
and invasion capacity among all the strains (p = 0.03). The KZN-S and F11-S strains 
displayed an equal adhesion and invasion capacity of M059K glial cells at a rate of 8 %, 
with no significant difference to that of the H37Rv strain (p = 0.38 and p = 0.37, 
respectively). The KZN-XDR, KZN-MDR and F28-MDR strains demonstrated 
significantly lower combined adhesion and invasion rates of 2 % (p = 0.005), 0.3 % (p < 
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0.001) and 2 % (p = 0.002), respectively. The Beijing-S strain showed no adhesion and 
invasion capacity following transmigration. 
The adhesion and invasion rate of all strains increased after 48 hours of incubation. The 
Beijing-XDR strain still displayed a significantly high adhesion and invasion rate at 93 
% (p < 0.001). The adhesion and invasion capacity of the KZN-XDR, KZN-S and F11-S 
strains were also significantly higher (p = 0.0003, p = 0.0002 and p = 0.048, respectively) 
than that of the H37Rv strain. There was no significant difference between adhesion and 
invasion capacity of the F28-MDR (p = 0.21) and KZN-MDR (p = 0.15) strains when 
compared to the H37Rv strain. 
 
 
Figure 3.3.2: Combined percent adhesion and invasion of M059K glial cells by 
different M. tuberculosis strains following transepithelial migration. Blue bars 
represent the 24-hour time point, and orange bars represent the 48-hour time point. 
 
0
20
40
60
80
100
120
P
er
ce
n
t 
a
d
h
es
io
n
 a
n
d
 i
n
v
a
si
o
n
M. tuberculosis strains
24 h
48 h
37 
 
3.4. Adhesion and invasion of M059K glial cells by different M. tuberculosis strains 
Using the invasion rates established in paragraph 3.2, the combined adhesion and invasion 
following transmigration at 48 hours was split into these two parts. The results are shown 
in Table 3.1. A significant difference in adhesion capacity was observed between the 
KZN-XDR (p = 0.10) and KZN-MDR (p = 0.000) strains in comparison to the H37Rv 
strain. There was no significant difference between the adhesion of KZN-S (p = 0.999), 
Beijing-XDR (p = 1.0), F11-S (p = 0.110) and F28-MDR (p = 0.984) strains and that of 
the H37Rv strain. No adhesion and invasion were observed for the Beijing-S strain. 
Comparisons of the invasion capacity of each strain with that of the H37Rv strain showed 
a significant difference for the KZN-MDR and F11-S strains only (p = 0.000). 
 
Table 3.1: Adhesion and invasion of glial cells by M. tuberculosis strains after the 
transmigration of an A549 monolayer represented by CFU counts in APPENDIX 2. 
M tuberculosis strain Adhesion Invasion 
H37Rv 
KZN-XDR 
KZN-MDR 
KZN-S 
Beijing-XDR 
Beijing-S 
F11-S 
F28-MDR 
4580 (92 %) 
35638 (93 %) * 
69843 (78 %) * 
290 (20 %)  
8008 (75 %)  
0 
26568 (37 %)  
10971 (79 %)  
421 (8 %) 
2473 (7 %)  
20268 (22 %) * 
1139 (80 %)  
2725 (25 %)  
0 
45654 (63 %) * 
2896 (21 %)  
 *P < 0.05 
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CHAPTER 4: DISCUSSION 
For CNS-TB to develop, M. tuberculosis needs to migrate from the alveoli of the lung to 
the CNS. Mycobacterium tuberculosis disseminates to other parts of the body by 
migration through or destruction of lung tissue (Danelishvili et al., 2003; Ryndak et al., 
2016). It has not been previously established that strains of M. tuberculosis differ in their 
ability to migrate from the lung to the brain. In this study, we evaluated the rate at which 
strains of M. tuberculosis, with different genotypes and drug resistance profiles, migrate 
through an alveolar epithelial cell monolayer and subsequently adhere to and invade a 
glial cell monolayer. We used a co-culture of alveolar epithelial cells and glial cells in a 
transwell system. Alveolar epithelial cells seeded on the insert membrane represented the 
lung side, glial cells seeded in the bottom of the well below the insert represented the 
brain, and the intermediate space represented the circulation. 
Various methods are used to evaluate the structural integrity and permeability of in vitro 
cultures of epithelial and endothelial cell monolayers or bilayers. The transepithelial/ 
transendothelial electrical resistance (TEER) is the most widely used method to assess 
the integrity of tight junctions in these cells (Wilhelm et al., 2011; Odijk et al., 2014; 
Chen et al., 2015; Paradis et al., 2016; Srinivasan et al., 2016). As described in the 
literature, the TEER method is reliable as it provides real-time measurements without 
damaging the cells. Measurements are carried out during the different stages of growth 
and differentiation of cells. Therefore, TEER values indicate the integrity of monolayers 
and thus the formation of tight junctions. Varying TEER values for different cell types 
and even for the same cell types in various studies have been reported (Hermanns et al., 
2004; Barar et al., 2005; Hermanns et al., 2009; Klein et al., 2013). These differences 
may be a result of factors such as temperature, the type of medium used and the cell 
passage number (Srinivasan et al., 2016). A general observation made is that TEER is 
higher in bilayers than in monolayers. Other methods used to assess integrity of in vitro 
barrier models include the use of electron microscopy and immunostaining of proteins 
characteristic of tight junctions using radioactive and nonradioactive labelled markers 
(Hermanns et al., 2004; Barar et al., 2005; Hermanns et al., 2009; Klein et al., 2013). 
While the use of labelled radioactive markers gives good sensitivity, their shortfall is that 
they have a short shelf-life and cannot be stored for long periods (Srinivasan et al., 2016). 
On the other hand, nonradioactive labelled markers such as dextrans have reduced 
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sensitivity (Srinivasan et al., 2016). It is suggested that these compounds can affect barrier 
integrity by interfering with transport processes and that the tested cells cannot be used 
for further experiments. In our study, we used the TEER method to assess A549 alveolar 
epithelial cell monolayer integrity. The TEER of A549 alveolar epithelial cell monolayer 
was measured daily until a stable value was detected. We observed that the A549 cell 
monolayer reached stability six days after seeding, then a drop in TEER from the seventh 
day indicated loss of monolayer integrity. 
In this study, results indicate that there are indeed differences in the invasion rate of glial 
cells between M. tuberculosis strains with different genotypes and resistance profiles. The 
Beijing strain showed an increase in invasion rate with an increasing level of resistance. 
On the contrary, the F15/LAM4/KZN strain showed a decrease in invasion rate with an 
increasing level of resistance. These findings are different from those reported for 
osteoblasts (Sarkar et al., 2016). The F28 strain showed a similar invasion rate as the 
MDR F15/LAM4/KZN strain. This may be because both are MDR strains and thus may 
have similar changes in their genome affecting invasion of these cells. Despite the XDR 
characteristic of the Beijing strain, it showed a similar invasion rate as the MDR strains. 
This suggests that the XDR Beijing strain may possess the same virulence factors as the 
MDR F15/LAM4/KZN and F28 strains in the pathogenesis of CNS-TB. Overall, the 
susceptible F15/LAM4/KZN strain demonstrated the highest invasion capacity of glial 
cells and the susceptible Beijing strain demonstrated the lowest. These findings indicate 
that the susceptible F15/LAM4/KZN strain, as well as the susceptible F11 strain, might 
be more likely to cause CNS-TB than the other strains while the susceptible Beijing strain 
is less virulent in CNS-TB. However, this needs further investigation based on strain-
specific resistance profiles and associated virulence factors. 
Differences in transepithelial migration were observed among the different strains. These 
differences were shown by the number of bacteria recovered from media collected below 
the transwell inserts following infection of A549 cells. We, therefore, consider the 
possibility of leakages in the insert membranes. We observed that the susceptible and 
XDR variants of the F15/LAM4/KZN strain transmigrate the alveolar epithelial cell 
monolayer more efficiently than the MDR variant. This is highly likely for the XDR 
variant as it has been established that highly resistant isolates are cytotoxic on A549 cells 
(Ashiru & Sturm, 2015). As for the decrease in the number of bacteria observed from 24 
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to 48 hours for the susceptible F15/LAM4/KZN isolate, we cannot come up with an 
explanation. If there was a problem with the integrity of the A549 monolayer or the 
membrane, one should expect the opposite. More rapid invasion into the glial cells can 
be ruled out as well since these cells are lysed before counting. We consider this isolate 
to have a similar transmigration rate as the laboratory H37Rv strain. For the Beijing strain, 
the XDR variant showed a high transmigration rate, while the susceptible variant showed 
no transmigration ability. Similar to the MDR F15/LAM4/KZN, the F28 and F11 strains 
showed a very low dissemination ability. Altogether, the XDR variants demonstrated a 
greater dissemination ability while the MDR variants demonstrated a lesser dissemination 
ability. We conclude that M. tuberculosis isolates are able to pass through the epithelial 
lining of the alveoli to other body sites by transepithelial migration. Also, these results 
show that the XDR isolates pass A549 cells very effectively. This is in keeping with what 
has been formerly reported by our group (Ashiru & Sturm, 2015). 
The BBB maintains homeostasis of the CNS. It is a physiological barrier that regulates 
the transport of different substances and molecules between the blood and the brain, and 
also plays a role in protection against pathogens (Wilhelm et al., 2011; Paradis et al., 
2016; Campisi et al., 2018). Different components make up the BBB. Brain endothelial 
cells held together by tight junctions are the major component of the BBB. However, 
these cells function together with a well-organised structure made up of astrocytes, 
pericytes, microglia, as well as a basement membrane (Wilhelm et al., 2011; Campisi et 
al., 2018). The basement membrane is made up of structural proteins such as the 
extracellular matrix proteins collagen, laminin, fibronectin and proteoglycans (Wilhelm 
et al., 2011). All these components are involved in the structural integrity of the BBB. 
Various models have been implemented to improve understanding of the physiology and 
function of the BBB. Most of these models involve the co-culture of brain endothelial 
cells and astrocytes or pericytes and in seldom microglial cells. Microglial cells belong 
to the macrophage lineage of cells and play a role in the immune response. Their presence 
in the BBB may be the target for macrophage-pathogens like M. tuberculosis to enter the 
meningeal space. Various study models have shown the immunological role of these cells 
in the CNS (Rock et al., 2005; Yang et al., 2007; Hernandez Pando et al., 2010; Cannas 
et al., 2011; Be et al., 2011; Qin et al., 2015; Francisco et al., 2015; Tucker et al., 2016). 
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Rock et al., (2005) and Yang et al., (2007) have proven that M. tuberculosis selectively 
infects microglial cells in comparison to astrocytes. 
Tuberculosis of the CNS is a fatal form of extrapulmonary TB. It is believed that after the 
deposition of M. tuberculosis in the alveoli of the lung, the bacilli disseminate to other 
body sites through bacteraemia (Rom & Garay, 2004). Whether disease develops or not 
depends on both the host’s immune response and bacterial virulence factors. From the 
circulation, M. tuberculosis must cross the BBB to cause CNS-TB. It is believed that M. 
tuberculosis crosses the BBB either as free bacilli or through infected macrophages (Jain 
et al., 2006). We hypothesised that different strains of M. tuberculosis would disseminate 
from the lung to the brain at different rates, using glial cells as the macrophages used for 
transport through the BBB. We, therefore, co-cultured alveolar epithelial cells and glial 
cells in a transwell system to mimic the natural development of CNS-TB. 
A significant increase in percent adhesion and invasion of glial cells was observed from 
24 hours to 48 hours following transepithelial migration of all strains. These low adhesion 
and invasion rates (< 10 %) are consistent with the low transmigration rates (< 5 %) 
observed. Our results indicate that XDR strains are the most invasive following 
transepithelial migration, followed by the susceptible strains and then the MDR strains. 
We further explored adhesion to glial cells and invasion of glial cells separately. We 
found out that both XDR and MDR isolates have high adhesion rates and low invasion 
rates during the period of investigation (48 hours), while the susceptible isolates have low 
adhesion rates and high invasion rates. We suggest that isolates with high adhesion and 
low invasion rates may need more time to invade or may use different adhesion molecules 
or ligands that do not trigger an invasion. This needs further investigation. 
The invasion capacity of M. tuberculosis into glial cells by organisms that have passed 
through the alveolar epithelial cells could differ from that of bacteria directly inoculated 
onto the glial cells. This could be due to structural changes on the surface of the bacteria 
while migrating through the epithelium. Therefore, there is a possibility that using the 
percent invasion without transmigration to calculate invasion from the combined 
adhesion and invasion figures may not be correct. However, the low number of bacteria 
that transmigrated did not allow for reliable differentiation between adhesion and 
invasion at that point. Our model does not include all the tissue layers involved in the 
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migration of M. tuberculosis from the alveoli to the brain. Further studies on the 
pathogenesis of CNS-TB should use extended models. 
To our knowledge, this is the first study to report on epithelial transmigration and 
subsequent invasion of glial cells involving different strains of M. tuberculosis. Very few 
studies based on the association between adhesion and invasion of cells and the 
susceptibility profile of different M. tuberculosis strains exist. Such studies have only 
been reported from our research group for osteoblasts (Sarkar et al., 2016) and alveolar 
and bronchial epithelial cells (Ashiru & Sturm, 2015). 
In conclusion, our results provide evidence that there are differences between strains of 
M. tuberculosis and that the changes in the genome that result in resistance also affect 
transepithelial migration to other body sites. 
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APPENDICES 
APPENDIX 1: METHODOLOGY 
1.1. Growth media 
1.1.1. Middlebrook 7H9 broth 
To prepare 1 L of Middlebrook 7H9 broth, 4.7 g of Middlebrook 7H9 powder was 
dissolved in 900 mL of distilled water containing 2 mL glycerol and autoclaved for 15 
minutes at 121 °C. After autoclaving, the media was cooled down to 55 °C and aseptically 
supplemented with 100 mL OADC. In order to confirm sterility prior to use, two drops 
of the broth were inoculated onto a blood agar plate and incubated overnight. 
1.1.2. Middlebrook 7H11 agar (Non-selective media) 
To prepare 1 L of Middlebrook 7H11 agar plates, 19 g of Middlebrook 7H11 powder was 
dissolved in 900 mL of distilled water containing 5 mL glycerol. The media was 
autoclaved for 15 minutes at 121 °C. After autoclaving, the media was placed in a water 
bath and cooled to 55 °C. After cooling, the media was aseptically supplemented with 
100 mL OADC and rapidly poured into 90 mm Petri dishes. Each Petri dish received 
between 20- and 22-mL agar. Once the media had cooled and solidified, sterility was 
confirmed by placing one plate in a CO2 incubator overnight. These plates were used to 
obtain the CFU count. 
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APPENDIX 2: CFU COUNTS 
2.1. Bacterial CFU counts obtained before the infection of A549 cells in the 
transmigration experiments. 
Strain number Inoculum CFU (CFU/ mL) 
(Transmigration experiments) 
 
H37Rv 2.6 x 106 
MODS 388 2.88 x 106 
MODS 688 1.96 x 109 
V4207 3.48 x105 
R4933 3.9 x 105 
TF 1516 1.78 x 105 
TF 832 2.38 x 108 
TF 44949 1.68 x 108 
 
 
2.2. Bacterial CFU counts obtained from the media collected after the infection of 
A549 cells in the transmigration experiments. 
Transmigration CFU 
Strain number 24 hours 48 hours 
 
12750 11400 11750 5600 5200 5250 
H37Rv 13950 12750 13100 7300 6100 5900 
 
10850 9800 9700 3900 4300 4600 
 
32000 31000 34000 19800 19800 17200 
(KZN-XDR) 47000 47000 41000 15850 15550 14400 
 
40000 42000 36000 11900 11300 11600 
 
640000 690000 710000 140000 145000 143000 
(KZN-MDR) 360000 380000 370000 140000 145000 143000 
 
550000 590000 370000 140000 145000 143000 
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8100 8900 7600 580 490 570 
(KZN-S) 7700 6750 6450 540 540 770 
 
7300 4600 5300 820 690 590 
 
8800 9250 8350 680 760 980 
(Beij-XDR) 4700 5200 4800 680 760 980 
 
6750 7225 6575 680 760 980 
 
0 0 0 0 0 0 
(Beij-S) 0 0 0 0 0 0 
 
0 0 0 0 0 0 
 
115000 112000 107000 57000 54500 57500 
(F11-S) 117000 103000 101000 57000 54000 63000 
 
74000 58000 60000 57000 55000 52000 
 
81000 75000 75000 11400 12500 13700 
(F28-MDR) 97000 93000 95000 11400 12500 13700 
 
144000 161000 104000 11400 12500 13700 
 
 
2.3. Bacterial CFU counts obtained from the glial cells lysed after the infection of 
A549 cells in the transmigration experiments. 
Combined Adhesion and Invasion CFU 
 
24 hours 48 hours 
 
690 785 760 9150 4120 4760 
H37Rv 1170 1065 1170 7230 6435 1235 
 
935 930 970 4335 3940 3800 
 
380 470 360 39000 37000 33000 
KZN-XDR 1180 1600 1500 29000 30000 34000 
 
380 440 510 54000 38000 49000 
 
1250 1405 1245 124000 116000 110000 
KZN-MDR 1020 940 980 60000 53000 56000 
 
1480 1870 1510 94000 87000 111000 
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360 440 510 1260 1530 1360 
KZN-S 1200 1100 900 1340 1350 1480 
 
310 330 280 1520 1470 1550 
 
8000 7850 6400 10400 11900 11000 
Beij-XDR 5200 4100 5250 12400 9900 9900 
 
6600 5975 5825 11100 10000 10000 
 
0 0 0 0 0 0 
Beij-S 0 0 0 0 0 0 
 
0 0 0 0 0 0 
 
3700 3900 2900 68000 68000 88000 
F11-S 7500 7400 7750 71000 68000 63000 
 
11300 10900 12600 72000 77000 75000 
 
1960 1880 1920 12800 14800 12500 
F28-MDR 1210 910 1060 13650 14250 13700 
 
1300 1130 1440 14500 13700 14900 
 
 
2.4. Bacterial CFU counts obtained before the infection of M059k glial cells in the 
invasion experiment. 
Strain number Inoculum CFU (CFU/ mL) 
(Adhesion experiment) 
 
H37Rv 5.75 x 104 
MODS 388 1.0 x 105 
MODS 688 3.6 x 104 
V4207 7.75 x104 
R4933 1.525 x 105 
TF 1516 2.025 x 104 
TF 832 1.4 x 105 
TF 44949 4.275 x 104 
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2.5. Bacterial CFU counts obtained after the infection of M059K glial cells in the 
invasion experiment. 
Adhesion CFU 
Strain number 24 hours 
H37Rv 4250 5400 5200 
 
4950 3600 3300 
 
5150 5950 5750 
KZN-XDR 6000 7650 4200 
 
5400 6000 6250 
 
7850 7400 7650 
KZN-MDR 8200 6950 8500 
 
8150 8650 8150 
 
8150 7800 8325 
KZN-S 60000 60000 52000 
 
62500 66000 61000 
 
72500 66500 55500 
Beij-XDR 38500 47000 37500 
 
35500 30500 39500 
 
39000 46500 34500 
Beij-S 200 200 50 
 
150 250 50 
 
50 100 200 
F11-S 78500 80000 81000 
 
97500 95000 91500 
 
93500 82500 97000 
F28-MDR 8400 8400 8400 
 
9300 9450 9100 
 
9100 9500 8700 
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APPENDIX 3: ETHICS APPROVAL 
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APPENDIX 4: TURNITIN ORIGINALITY REPORT 
Please note that the similarity index of the Turnitin originality report is 18 %. However, 
the system has identified immaterial words; such as, the name of the university, school 
and college, as well as chapter headings, abbreviated terms, the names of consumables, 
and manufacturers. 
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